ALT:NSD-Altimmune, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.03

Change

-0.50 (-3.99)%

Market Cap

USD 0.40B

Volume

0.67M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.69 (-0.26%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-7.73 (-1.37%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+0.16 (+0.09%)

USD31.19B N/A N/A
MRNA Moderna, Inc

-1.99 (-2.96%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-1.55 (-3.71%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

-0.41 (-0.36%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+1.89 (+0.69%)

USD24.64B N/A N/A
GMAB Genmab A/S

-1.06 (-2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.13 (+0.15%)

USD19.69B N/A N/A
INCY Incyte Corporation

-0.90 (-1.05%)

USD18.80B 47.64 35.20

ETFs Containing ALT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 536.51% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 536.51% 97% A+ 98% A+
Trailing 12 Months  
Capital Gain 498.51% 95% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 498.51% 95% A 98% A+
Trailing 5 Years  
Capital Gain -70.94% 36% F 15% F
Dividend Return 210.87% 100% A+ 100% A+
Total Return 139.93% 85% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 18.86% N/A N/A N/A N/A
Dividend Return 40.30% N/A N/A N/A N/A
Total Return 59.16% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 221.05% N/A N/A N/A N/A
Risk Adjusted Return 26.76% N/A N/A N/A N/A
Market Capitalization 0.40B 59% F 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.82 68% D+ 89% B+
Price/Book Ratio 5.19 42% F 26% F
Price / Cash Flow Ratio -41.95 91% A- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -52.58% 61% D- 23% F
Return on Invested Capital -43.86% 68% D+ 21% F
Return on Assets -20.20% 68% D+ 20% F
Debt to Equity Ratio 4.10% 78% C+ 84% B
Technical Ratios  
Short Ratio 0.64 82% B- 81% B-
Short Percent 3.65% 69% D+ 47% F
Beta 1.42 55% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector